Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Bronchopulmonary Dysplasia – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 4 PAGES: 52

Bronchopulmonary Dysplasia - Pipeline Review, H1 2012', provides an overview of the Bronchopulmonary Dysplasia therapeutic pipeline. This report provides information on the therapeutic development for Bronchopulmonary Dysplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchopulmonary Dysplasia. 'Bronchopulmonary Dysplasia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									    Bronchopulmonary Dysplasia – Pipeline Review, H1
                        2012


                                                                                          Reference Code: GMDHC1976IDB
                                                                                              Publication Date: April 2012




Bronchopulmonary Dysplasia – Pipeline Review, H1 2012                                         GMDHC1976IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Bronchopulmonary Dysplasia – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 5
Introduction......................................................................................................................................................................................... 6
    Global Markets Direct Report Coverage ........................................................................................................................................ 6
Bronchopulmonary Dysplasia Overview ............................................................................................................................................. 7
Therapeutics Development................................................................................................................................................................. 8
    An Overview of Pipeline Products for Bronchopulmonary Dysplasia ............................................................................................. 8
Bronchopulmonary Dysplasia Therapeutics under Development by Companies ............................................................................. 10
Bronchopulmonary Dysplasia Therapeutics under Investigation by Universities/Institutes .............................................................. 11
Late Stage Products ......................................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Mid Clinical Stage Products.............................................................................................................................................................. 14
    Comparative Analysis .................................................................................................................................................................. 14
Early Clinical Stage Products ........................................................................................................................................................... 15
    Comparative Analysis .................................................................................................................................................................. 15
Pre-Clinical Stage Products.............................................................................................................................................................. 16
    Comparative Analysis .................................................................................................................................................................. 16
Bronchopulmonary Dysplasia Therapeutics – Products under Development by Companies ........................................................... 17
Bronchopulmonary Dysplasia Therapeutics – Products under Investigation by Universities/Institutes ............................................ 18
Companies Involved in Bronchopulmonary Dysplasia Therapeutics Development .......................................................................... 19
    MediPost Co., Ltd. ....................................................................................................................................................................... 19
    Syntrix Biosystems, Inc. .............................................................................................................................................................. 20
    Ikaria Inc. ..................................................................................................................................................................................... 21
Bronchopulmonary Dysplasia – Therapeutics Assessment .............................................................................................................. 22
    Assessment by Monotherapy Products ....................................................................................................................................... 22
    Assessment by Combination Products ........................................................................................................................................ 23
    Assessment by Route of Administration ...................................................................................................................................... 24
    Assessment by Molecule Type .................................................................................................................................................... 26
Drug Profiles..................................................................................................................................................................................... 28
    Pneumostem - Drug Profile ......................................................................................................................................................... 28
         Product Description................................................................................................................................................................. 28
         Mechanism of Action ............................................................................................................................................................... 28
         R&D Progress ......................................................................................................................................................................... 28
    Chemotaxis Inhibitors - Drug Profile ............................................................................................................................................ 30
         Product Description................................................................................................................................................................. 30
         Mechanism of Action ............................................................................................................................................................... 30
         R&D Progress ......................................................................................................................................................................... 30
    Azithromycin - Drug Profile .......................................................................................................................................................... 31
         Product Description................................................................................................................................................................. 31
         Mechanism of Action ............................................................................................................................................................... 31
         R&D Progress ......................................................................................................................................................................... 31



Bronchopulmonary Dysplasia – Pipeline Review, H1 2012                                                                                              GMDHC1976IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                    Page(2)
Bronchopulmonary Dysplasia – Pipeline Review, H1 2012




    Zileuton - Drug Profile.................................................................................................................................................................. 32
        Product Description................................................................................................................................................................. 32
        Mechanism of Action ............................................................................................................................................................... 32
        R&D Progress ......................................................................................................................................................................... 32
    Budesonide - Drug Profile ........................................................................................................................................................... 33
        Product Description................................................................................................................................................................. 33
        Mechanism of Action ............................................................................................................................................................... 33
        R&D Progress ......................................................................................................................................................................... 33
    IK-3001 - Drug Profile .................................................................................................................................................................. 34
        Product Description................................................................................................................................................................. 34
        Mechanism of Action ............................................................................................................................................................... 34
        R&D Progress ......................................................................................................................................................................... 34
    Dexamethasone - Drug Profile .................................................................................................................................................... 36
        Product Description................................................................................................................................................................. 36
        Mechanism of Action ............................................................................................................................................................... 36
        R&D Progress ......................................................................................................................................................................... 36
    Infasurf - Drug Profile .................................................................................................................................................................. 37
        Product Description................................................................................................................................................................. 37
        Mechanism of Action ............................................................................................................................................................... 37
        R&D Progress ......................................................................................................................................................................... 37
    L-Citrulline - Drug Profile ............................................................................................................................................................. 38
        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progress ......................................................................................................................................................................... 38
    Hydrocortisone - Drug Profile ....................................................................
								
To top